LUS AT BIRTH IN INFANTS BORN BEFORE 26 WEEKS
Launched by ANDALUZ HEALTH SERVICE · Apr 30, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called "LUS" for infants who are born extremely early, specifically those born before 26 weeks of pregnancy. The goal is to see how this treatment affects their breathing and overall health, especially when they also need a medication called surfactant to help with respiratory distress syndrome, a common issue for such premature babies. All participating infants will receive the LUS treatment right after they are born, before they get their first dose of surfactant.
To participate in this trial, infants must be born before 26 weeks at one of the hospitals involved in the study. However, babies who have already received surfactant before getting LUS, or those facing serious health issues or malformations, cannot join. Families of eligible infants can expect close monitoring of their baby's breathing support needs during the trial. This study is important because it may help improve care for very premature infants, leading to better health outcomes for them in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Infants born before 26 weeks at any of the participant hospitals.
- Exclusion Criteria:
- • received surfactant before LU
- • redirection of care
- • severe malformations of cromosomopathies
- • unable to perform LU
About Andaluz Health Service
The Andaluz Health Service (Servicio Andaluz de Salud, SAS) is a leading public healthcare organization in Spain, dedicated to providing high-quality medical services and advancing health research. As a clinical trial sponsor, SAS plays a pivotal role in the development and evaluation of innovative therapies and medical interventions, facilitating collaborations between healthcare professionals, academic institutions, and the pharmaceutical industry. Committed to enhancing patient care and outcomes, SAS adheres to rigorous ethical standards and regulatory guidelines, ensuring that all clinical trials are conducted with integrity and a focus on participant safety. Through its research initiatives, the Andaluz Health Service aims to contribute significantly to medical knowledge and the improvement of public health in Andalusia and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported